Psoriasis and urticaria are chronic inflammatory skin diseases, which account for a substantial socio-economic burden and severely affect patients' quality of life. According to the respective German guidelines, biologicals can be used for the treatment of severe forms of these diseases. However, only a minority of patients receive this advised treatment.